--- title: "Atea Pharmaceuticals (AVIR) news: buyback" url: "https://aibio.space/companies/atea-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AVIR buyback news: Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group. Atea Pharmaceuticals, Inc." --- AVIR Atea Pharmaceuticals, Inc. NASDAQ · United States # Atea Pharmaceuticals (AVIR) news AVIR buyback news Distress · 2025-04-17 ## [Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group](https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/) The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going. ## Latest Atea Pharmaceuticals news We have not published a story on Atea Pharmaceuticals yet. When there is news, it will appear here. ## Atea Pharmaceuticals at a glance - **Ticker**: AVIR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $219.5 million ### Related companies - [Sigyn Therapeutics](https://aibio.space/companies/sigyn-therapeutics/) OTC: SIGY - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) NASDAQ: XLO - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) NASDAQ: TGTX - [PRAXSYN CORP](https://aibio.space/companies/praxsyn/) OTC: PXYN - [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) NASDAQ: TARS - [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) NASDAQ: TNYA - [Johnson & Johnson](https://aibio.space/companies/johnson-johnson/) NYSE: JNJ - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD ### Also on NASDAQ - [BIO-TECHNE](https://aibio.space/companies/bio-techne/) TECH - [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) CUE - [Apollomics](https://aibio.space/companies/apollomics/) APLM - [Longeveron](https://aibio.space/companies/longeveron/) LGVN - [Citius Oncology](https://aibio.space/companies/citius-oncology/) CTOR - [SL Science Holding](https://aibio.space/companies/sl-science/) SLBT ## Atea Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$148.0 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | [$144.1 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | | Net income (loss) | [-$158.3 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | [-$168.4 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | | Cash from operations | [-$132.0 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | [-$135.5 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | | Cash and equivalents | [$95.7 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526347021/) | [$64.7 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | | Short-term investments | [$206.1 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526347021/) | [$390.0 million](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $76.5 million, plus short-term investments of $142.9 million, $219.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Atea Pharmaceuticals Does Atea Pharmaceuticals have a share buyback? Our latest story on this, dated Apr 17, 2025: "Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/). What is the ticker symbol of Atea Pharmaceuticals? Atea Pharmaceuticals, Inc. trades under the ticker AVIR on NASDAQ. Where is Atea Pharmaceuticals listed? Atea Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Atea Pharmaceuticals? The SEC Central Index Key (CIK) for Atea Pharmaceuticals, Inc. is 1593899. Its filings are on SEC EDGAR. How many shares does Atea Pharmaceuticals have outstanding? 80,204,699 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Atea Pharmaceuticals listed under? Our directory records Atea Pharmaceuticals, Inc. under United States. What does Atea Pharmaceuticals do? Our directory classifies Atea Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Atea Pharmaceuticals? The ISIN recorded for Atea Pharmaceuticals, Inc. is US04683R1068. Does aibio.space cover Atea Pharmaceuticals? aibio.space lists Atea Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Atea Pharmaceuticals incorporated? SEC records list its state or country of incorporation as MA. Is Atea Pharmaceuticals profitable? Atea Pharmaceuticals, Inc. reported a net loss of $158.3 million for the fiscal year ended Dec 31, 2025, and used $132.0 million of cash in operations, per its annual report to the SEC. How much does Atea Pharmaceuticals spend on research and development? $148.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Atea Pharmaceuticals have? $219.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Atea Pharmaceuticals (AVIR) stock news? Our latest story on Atea Pharmaceuticals, dated Apr 17, 2025: "Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group". The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going. [Source](https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/). Is Atea Pharmaceuticals in financial distress? Our latest distress story, dated Apr 17, 2025: "Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group". The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going. [Source](https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/). ## Investor discussion: Atea Pharmaceuticals Members talk about Atea Pharmaceuticals (AVIR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Atea Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2025-04-17 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/d915073dex991.htm) 2. 2024-11-07 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1593899/000119312524253272/d899727ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AVIR on TradingView](https://www.tradingview.com/symbols/NASDAQ-AVIR/). ## SEC filings and registration - **SEC name**: Atea Pharmaceuticals, Inc. - **CIK**: 1593899 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AVIR (Nasdaq) - **State or country of incorporation**: MA - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 225 FRANKLIN STREET, BOSTON, MA, 02110 - **Phone**: (857) 284-8891 - **Shares outstanding**: 80,204,699 as of 2026-08-10 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1593899/000119312526347021/avir-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663d8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/d11075d8k.htm) filed 2026-06-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1593899/000119312526219678/avir-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/d12234d8k.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1593899/000119312526182293/avir-20260427.htm) filed 2026-04-27 - [10-K](https://www.sec.gov/Archives/edgar/data/1593899/000119312526094159/avir-20251231.htm) filed 2026-03-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/d118938d8k.htm) filed 2026-03-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001593899), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Atea Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AVIR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Atea Pharmaceuticals, Inc. - **Ticker**: AVIR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US04683R1068 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AVIR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/atea-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Atea Pharmaceuticals (AVIR) news: buyback", 2026-10-31, https://aibio.space/companies/atea-pharmaceuticals/